Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers

Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The as...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawelczyk, Konrad, Piotrowska, Aleksandra, Ciesielska, Urszula, Jablonska, Karolina, Glatzel-Plucinska, Natalia, Grzegrzolka, Jedrzej, Podhorska-Okolow, Marzenna, Dziegiel, Piotr, Nowinska, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413136/
https://www.ncbi.nlm.nih.gov/pubmed/30769852
http://dx.doi.org/10.3390/ijms20040824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413136/
https://www.ncbi.nlm.nih.gov/pubmed/30769852
http://dx.doi.org/10.3390/ijms20040824

Ejemplares similares